Ovarian Cancer Articles

Markman Proposes Shift in Ovarian Cancer Clinical Trial Paradigm
Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer. 
Letrozole Maintenance Therapy Improves RFS in Ovarian Cancer
Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.
Targeting Tumor Vasculature in Ovarian Cancer
Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.
Future of Immunotherapy in Ovarian Cancer to Include Combinations
Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.
FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer
The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Time Between Neoadjuvant and Adjuvant Chemo Impacts OS in Ovarian Cancer
Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.
 
Niraparib Approved in Europe for Ovarian Cancer
The European Commission has approved niraparib as a maintenance therapy for women with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer
Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.
PARPs Bring Excitement to Ovarian Treatment
PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.
How Reliable Is PD-L1 Expression as a Predictor of Immune Response?
There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.
Publication Bottom Border
Border Publication
x